Vera Therapeutics, Inc. (VERA) stock
Close on Nov 11, 2026Market cap $2.20BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.20B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.59
- Dividend yield
- –
- Free cash flow yield
- -17.12%
Fundamentals
- Net income
- -$415.31M
- EPS, diluted
- -$5.90
- Free cash flow
- -$376.05M
- Book value per share
- $4.62
- Diluted shares
- 72M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $30.03
- Open
- $30.17
- Day's range
- $29.76 – $30.62
- Volume
- 1,710,199
- Average volume (20 days)
- 1,586,633
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Nov 2021)
- Beta (5 years)
- 0.84
- 52-week range
- $26.38 – $56.05
- RSI (14 days)
- 50.5
- Volatility (1 year)
- 59.2%
- Relative volume
- 0.81×
- WACC
- 9.1%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VERA | S&P 500 | Difference | VERA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.0% | -2.4% | +4.4 pts | ||
| 3 months | +0.6% | -1.2% | +1.8 pts | ||
| Year to date | -39.8% | +12.3% | −52.1 pts | ||
| 1 year | +2.6% | +12.4% | −9.9 pts | ||
| 3 years | +151.1% | +78.8% | +72.3 pts | +35.9% | +21.4% |
| 5 years | +36.9% | +75.2% | −38.2 pts | +6.5% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vera Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
About Vera Therapeutics
Pharmaceutical Preparations
Vera Therapeutics, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing therapies for individuals with severe immunological conditions. The company's primary product candidate is atacicept, a fusion protein designed for at-home self-administration via subcutaneous injection to treat autoimmune kidney conditions, most notably immunoglobulin A nephropathy. In addition to atacicept, its development programs involve investigational candidates such as MAU868 and VT-109 under licensing agreements. The company operates in the biotechnology sector and aims its investigational therapies at patients suffering from serious autoimmune and kidney disorders.
Company profile, executives and historyVera Therapeutics stock: common questions
What is Vera Therapeutics's stock price?
VERA closed at $30.48 on Nov 11, 2026, up 1.50% on the day. Over the past 52 weeks it traded between $26.38 and $56.05.
What is Vera Therapeutics's market cap?
Vera Therapeutics was worth $2.20B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VERA's P/E ratio?
Vera Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.90), so it has no meaningful P/E ratio.
Does Vera Therapeutics pay a dividend?
No. Vera Therapeutics has not paid a cash dividend over the last twelve months.
When does Vera Therapeutics report earnings next?
Vera Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VERA stock performed over the past year?
Including dividends, VERA returned +2.6% over the past year, against +12.4% for the S&P 500.
How many VERA shares are sold short?
12M shares were sold short at the latest FINRA report, 19.80% of the float, or 8.5 days of average trading volume.
Who are Vera Therapeutics's competitors?
Companies most similar to Vera Therapeutics by business, industry and size include JBIO, VRDN, CLYM, NKTX, NKTR.
See a number that looks wrong?